N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU

[1]  J. Schellens,et al.  A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. , 2009, Biomedical chromatography : BMC.

[2]  Hermes Licea-Perez,et al.  Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  L. Fazli,et al.  Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy , 2009, Cancer Chemotherapy and Pharmacology.

[4]  K. Kurashina,et al.  Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo , 2008, International Journal of Clinical Oncology.

[5]  T. Shirasaka.  Development History and Concept of an Oral Anticancer Agent S-1 (TS-1®): Its Clinical Usefulness and Future Vistas , 2008, Japanese journal of clinical oncology.

[6]  Zhirong Zhang,et al.  In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Ming-Hui Chen,et al.  Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity , 2008, Anti-cancer drugs.

[8]  E. Alba,et al.  A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. , 2008, Current drug metabolism.

[9]  N. Zhang,et al.  Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes. , 2008, International journal of pharmaceutics.

[10]  M. Makuuchi,et al.  Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil. , 2007, European journal of pharmacology.

[11]  K. Caca,et al.  Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride , 2007, Cancer Chemotherapy and Pharmacology.

[12]  M. Makuuchi,et al.  Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil. , 2006, World Journal of Gastroenterology.

[13]  J. Verweij,et al.  A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors , 2006, Cancer Chemotherapy and Pharmacology.

[14]  E. Richardet,et al.  Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks: A Feasibility Study in Metastatic Colorectal Cancer Patients , 2006, American journal of clinical oncology.

[15]  H. Lenz,et al.  Should Continuous Infusion 5-Fluorouracil Become the Standard of Care in the USA as It Is in Europe? , 2006, Cancer investigation.

[16]  S. Guichard,et al.  Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  R. Nave,et al.  Identification of enzymes involved in Phase I metabolism of ciclesonide by human liver microsomes , 2005, European Journal of Drug Metabolism and Pharmacokinetics.

[18]  M. Das,et al.  Mechanism to study 1:1 stoichiometry of NADPH and alkoxyphenoxazones metabolism spectrophotometrically in subcellular biological preparations. , 2004, Biochimica et biophysica acta.

[19]  S. Tokudome,et al.  IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5′-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER , 2004, Drug Metabolism and Disposition.

[20]  N. Funata,et al.  Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer , 2004, British Journal of Cancer.

[21]  Yang Zhang,et al.  [Phase III clinical study of a new anticancer drug atofluding]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.

[22]  S. Ozawa,et al.  Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver , 2002, Cancer Chemotherapy and Pharmacology.

[23]  M. Das,et al.  A novel approach to study the activity and stoichiometry simultaneously for microsomal pentoxyresorufin‐O‐dealkylase reaction , 2002, FEBS letters.

[24]  W. Bubb,et al.  Synthesis of 5-fluoropyrimidines , 1974 .

[25]  C. Heidelberger,et al.  THE SYNTHESIS OF 5-FLUOROPYRIMIDINES , 1957 .

[26]  N. Zhang,et al.  Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. , 2008, Journal of drug targeting.